Clinical Characteristics and Pharmacokinetics of Purified Soy Isoflavones: Multiple-Dose Administration to Men with Prostate Neoplasia
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
A phase I clinical trial was conducted to determine the safety, pharmacokinetic parameters, and efficacy of orally administered isoflavones (genistein and daidzein, potential cancer chemotherapeutic agents) over a 3-mo period in men with prostate neoplasia. Twenty men, ages 40 and above, with stage B, C, or D adenocarcinoma of the prostate were treated with a multiple-dose regimen of a soy isoflavone formulation (delivering approximately 300 or 600 mg/day genistein and half this much daidzein) for 84 days. The delivered dose of isoflavones was more than 10-fold higher than that typically taken by prostate cancer patients. In men with prostate cancer, relatively minor side effects of chronic isoflavone treatment were observed including some estrogenic effects (breast changes, increased frequency of hot flashes). Serum dehydroepiandrosterone was decreased by 31.7% (P = 0.0004) at the end of treatment. Except for those subjects whose prostate-specific antigen (PSA) values were below 0.4 ng/ml, subjects had a history of increasing PSA levels prior to the trial. This increase continued during the trial both while on soy isoflavones and after treatment was discontinued. On average the rate of rise accelerated after soy isoflavones were discontinued, but that difference did not attain statistical significance. Genistein and daidzein were rapidly cleared from plasma and excreted in urine. Pharmacokinetic data for chronic dose administration were similar to single-dose administration for the isoflavones investigated except that we observed slightly longer circulation time for daidzein.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genistein Affects ERβ- But Not ERα-Dependent Gene Expression in the Hypothalamus
Patisaul, H. B., Melby, M., Whitten, P. L., & Young, L. J. (2002) · Endocrinology · doi:10.1210/endo.143.6.8843 · Cited by 108
Cited by
Křížová, L., Dadáková, K., Kašparovská, J., & Kašparovský, T. (2019) · Molecules · doi:10.3390/molecules24061076 · Cited by 692
Multi-targeted therapy of cancer by genistein
Banerjee, S., Li, Y., Wang, Z., & Sarkar, F. H. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.052 · Cited by 620
Targeting NOX, iNOS and COX-2 in inflammatory cells: chemoprevention using food phytochemicals
Murakami, A., & Ohigashi, H. (2007) · International Journal of Cancer · doi:10.1002/ijc.23161 · Cited by 478
Estimated Asian adult soy protein and isoflavone intakes
Messina, M., Nagata, C., & Wu, A. H. (2006) · Nutrition and Cancer · doi:10.1207/s15327914nc5501_1 · Cited by 435
Thomasset, S. C., Berry, D. P., Garcea, G., Marczylo, T., Steward, W. P., & Gescher, A. J. (2007) · International Journal of Cancer · doi:10.1002/ijc.22419 · Cited by 406
Metadata
- Authors
- Fischer, L., Mahoney, C., Jeffcoat, A. R., Koch, M. A., Thomas, B. F., Valentine, J. L., Stinchcombe, T., Boan, J., Crowell, J. A., & Zeisel, S. H.
- Venue
- Nutrition and Cancer
- Publisher
- Informa UK Limited
- Published
- 2004-03
- Volume
- 48
- Issue
- 2
- Pages
- 160-170
- ISSN
- 0163-5581 (ISSN-L)
- 1532-7914
- OpenAlex
- W2159351478
- Cited by
- 102
- References
- 1
- FWCI
- 4.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.